See the DrugPatentWatch profile for cosentyx

The recommended dosage frequency for Cosentyx (secukinumab) may vary depending on the condition being treated. For adults with moderate to severe plaque psoriasis, the usual dosage is 300 mg administered by subcutaneous injection at Weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks. For patients with active psoriatic arthritis or active ankylosing spondylitis, the recommended dosage is 150 mg or 300 mg administered by subcutaneous injection at Weeks 0, 1, 2, 3, and 4, followed by 150 mg or 300 mg every 4 weeks.

It is important to note that the dosage may be adjusted based on the patient's response to treatment and tolerability. Additionally, patients should be closely monitored by a healthcare professional while taking Cosentyx.

It is also important to note that, according to DrugPatentWatch.com, Cosentyx is currently patent protected in the United States until 2025, which means that generic versions of the drug are not yet available on the market.

Sources:

* [Cosentyx (secukinumab) injection, for subcutaneous use : Medication Guide](https://www.fda.gov/media/94330/download)
* [DrugPatentWatch.com: Cosentyx (secukinumab)](https://www.drugpatentwatch.com/drugs/cosentyx)